Genenta Science S.p.A. American Depositary Shares

Genenta Science (Nasdaq: GNTA), transforming into Saentra Forge, has signed definitive agreements to invest €6.0 million in Sòphia High Tech, an Italian aerospace and defense manufacturer. The investment will give Genenta a 19.9% stake initially and 51% stake upon second tranche closing. Sòphia HT, which reported €6.29 million in 2024 reven...

Genenta Science, transitioning to Saentra Forge, has entered into a binding offer to acquire Italian aerospace and defense manufacturer Sòphia High Tech through two reserved capital increases totaling EUR 6.0 million, with the goal of reaching a controlling stake upon achieving defined performance milestones. Sòphia High Tech, founded in 2013 a...

Genenta Science (Nasdaq: GNTA), transforming into Saentra Forge (Nasdaq: SAEN), announced the appointment of Paolo Salvato to ATC's Board of Directors and is pursuing majority-control acquisitions in national-security sectors including defense, aerospace, and cybersecurity. The company also announced that Nature Medicine accepted a manuscript on ...

Genenta Science reported positive survival metrics in its TEM-GBM study for glioblastoma patients, with 44% reaching 18-month survival and one patient surviving 39 months after treatment. The company also announced approximately $30 million in cash and short-term investments following a recent direct offering.

Genenta Science has entered into a securities purchase agreement to sell 4,285,715 American Depositary Shares at $3.50 per share, raising approximately $15 million for working capital and general corporate purposes.